EnteroBiotix newsroom

News & press releases

News

EnteroBiotix Completes £27m Financing Round to Advance Clinical Trials

4 Apr 2024

EnteroBiotix Completes £27m Financing Round to Advance Clinical Trials

4 Apr 2024

4 Apr 2024

EnteroBiotix Initiates Phase 2 Study of EBX-102-02 in Patients with Irritable Bowel Syndrome (IBS)

3 Apr 2024

EnteroBiotix Initiates Phase 2 Study of EBX-102-02 in Patients with Irritable Bowel Syndrome (IBS)

3 Apr 2024

3 Apr 2024

EnteroBiotix appoints Elmar Schnee as Executive Chairman

17 Jul 2023

EnteroBiotix appoints Elmar Schnee as Executive Chairman

17 Jul 2023

17 Jul 2023

EnteroBiotix Initiates Phase 2 study of microbiome drug EBX-102 in liver cirrhosis and hepatic encephalopathy

28 Mar 2023

EnteroBiotix Initiates Phase 2 study of microbiome drug EBX-102 in liver cirrhosis and hepatic encephalopathy

28 Mar 2023

28 Mar 2023

EnteroBiotix partners with Imperial College London to advance microbiome therapeutics

10 Nov 2022

EnteroBiotix partners with Imperial College London to advance microbiome therapeutics

10 Nov 2022

10 Nov 2022

EnteroBiotix receives MHRA MIA (IMP) licensure of state-of-the-art GMP manufacturing facility for producing microbiome therapeutics

11 Oct 2022

EnteroBiotix receives MHRA MIA (IMP) licensure of state-of-the-art GMP manufacturing facility for producing microbiome therapeutics

11 Oct 2022

11 Oct 2022

EnteroBiotix CEO features on Labiotech’s Beyond Biotech podcast talking about mastering the microbiome

29 Jul 2022

EnteroBiotix CEO features on Labiotech’s Beyond Biotech podcast talking about mastering the microbiome

29 Jul 2022

29 Jul 2022

EnteroBiotix CEO completes 500 pull-ups and press-ups to raise funds for The Brain Charity

11 Jul 2022

EnteroBiotix CEO completes 500 pull-ups and press-ups to raise funds for The Brain Charity

11 Jul 2022

11 Jul 2022

EnteroBiotix Appoints David Lawrence to its Board of Directors

30 Jun 2022

EnteroBiotix Appoints David Lawrence to its Board of Directors

30 Jun 2022

30 Jun 2022

16 Jun 2022

Number 2 trademark fully registered in key territories, categories and classes

16 Jun 2022

16 Jun 2022

EBX in the news

News

EnteroBiotix article features in Medicine Maker

2 Dec 2022

EnteroBiotix article features in Medicine Maker

2 Dec 2022

2 Dec 2022

EnteroBiotix article features in the European Biopharmaceutical Review

14 Sep 2022

EnteroBiotix article features in the European Biopharmaceutical Review

14 Sep 2022

14 Sep 2022

EnteroBiotix CEO features in Forbes 30 under 30

3 May 2022

EnteroBiotix CEO features in Forbes 30 under 30

3 May 2022

3 May 2022

EnteroBiotix CEO featured on The Pharma Letter podcast talking about mastering the microbiome

10 Mar 2022

EnteroBiotix CEO featured on The Pharma Letter podcast talking about mastering the microbiome

10 Mar 2022

10 Mar 2022

EnteroBiotix completes new manufacturing facility focused on gut microbiome therapies

27 Oct 2021

EnteroBiotix completes new manufacturing facility focused on gut microbiome therapies

27 Oct 2021

27 Oct 2021

EnteroBiotix secures $21.5M series A to advance microbiome drug pipeline

7 Sep 2021

EnteroBiotix secures $21.5M series A to advance microbiome drug pipeline

7 Sep 2021

7 Sep 2021

EnteroBiotix raises more than $21M in Series A

7 Sep 2021

EnteroBiotix raises more than $21M in Series A

7 Sep 2021

7 Sep 2021

Events

News

EnteroBiotix will be attending BIO Europe 2024, Stockholm

EnteroBiotix will be attending BIO Europe 2024, Stockholm

EnteroBiotix will be attending BIO Future 2024, New York

EnteroBiotix will be attending BIO Future 2024, New York

EnteroBiotix will be attending BIO International Convention 2024, San Diego

EnteroBiotix will be attending BIO International Convention 2024, San Diego

Find out more about our donor programme. Visit Number2.org